SAN DIEGO, Sept. 28, 2022 (GLOBE NEWSWIRE) —

The class: Law firm for shareholder rights Robbins LLP reminds investors that a shareholder on behalf of all persons and entities who purchased or otherwise acquired common stock of Medtronic PLC (NYSE:MDT) between June 8, 2019 and May 25, 2022 for violations of the Securities Exchange Act of Medtronic is a medical device company. Its products include the MiniMed insulin pump system for treating diabetes, including the MiniMed 780G model. Medtronic is currently seeking regulatory approval for the MiniMed 780G.

If you would like more information about Medtronic PLC’s wrongdoing, click here here.

What is it about in this case: Medtronic PLC (MDT) had inadequate quality control systems, delaying approval of its MiniMed 780G device and causing financial damage to shareholders

According to the lawsuit, during the class action, the defendants repeatedly assured investors that the MiniMed 780G model was “on track” for U.S. Food and Drug Administration (the “FDA”) approval and would provide the company with the advantage it needed a closing a growing gap with its competitors in the diabetes market.

On December 15, 2021, Medtronic announced that it had received a warning letter from the FDA regarding its Northridge, California facility. The warning letter followed an FDA inspection related to the recall of the company’s MiniMed 600 series and focused on “the inadequacy of specific medical device quality system requirements.” . . in risk assessment, corrective and preventive actions, complaint handling, device recalls and adverse event reporting.” As a result of the warning letter, Medtronic lowered its forecast for its diabetes group. As a result of this news, Medtronic’s common stock price fell $6.75 per share, or approximately 6%, to close at $104.94 per share on December 15, 2021.

On May 26, 2022, Medtronic released its financial results for the fourth quarter and…